# Cognito Therapeutics, Inc.

> Cognito Therapeutics is a Cambridge, Massachusetts clinical-stage neurotechnology company spun out of MIT that develops non-invasive, wearable therapy for neurodegenerative disease. Its lead product, Spectris, delivers precise gamma-frequency light and sound stimulation through connected glasses and headphones to evoke gamma brain oscillations, with the goal of slowing cognitive and functional decline in Alzheimer's disease. Spectris AD holds FDA Breakthrough Device Designation and is being evaluated in the HOPE Study, described as the largest medical device trial focused solely on Alzheimer's disease.

- **Founded:** 2016
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Li-Huei Tsai (Scientific Co-Founder (MIT Professor of Neuroscience)), Ed Boyden (Scientific Co-Founder (MIT Professor))
- **Team size:** 64 employees
- **Products:** Spectris (Spectris AD), Gamma sensory stimulation platform
- **Notable:** Received FDA Breakthrough Device Designation for Spectris AD (2021) for cognitive and functional symptoms of Alzheimer's disease., Completed enrollment of 670 participants in the HOPE Study, described as the largest medical device trial focused solely on Alzheimer's disease., OVERTURE trial data showed Spectris slowed decline in daily function and cognition and preserved corpus callosum / white-matter structure vs sham.

## Products & services

- **Spectris (Spectris AD)** — A non-invasive, wearable neuromodulation device that delivers proprietary gamma-frequency light and sound stimulation through connected glasses and headphones to evoke EEG-confirmed gamma brain oscillations. Designed for daily at-home use to slow cognitive and functional decline in Alzheimer's disease. Holds FDA Breakthrough Device Designation.
- **Gamma sensory stimulation platform** — A therapeutic platform delivering personalized, non-invasive neuromodulation to evoke gamma oscillations, intended to address a range of neurodegenerative diseases beyond Alzheimer's.

## Achievements

- Received FDA Breakthrough Device Designation for Spectris AD (2021) for cognitive and functional symptoms of Alzheimer's disease.
- Completed enrollment of 670 participants in the HOPE Study, described as the largest medical device trial focused solely on Alzheimer's disease.
- OVERTURE trial data showed Spectris slowed decline in daily function and cognition and preserved corpus callosum / white-matter structure vs sham.
- Raised $105M Series C in March 2026; over $273M raised in total.
- Spun out of pioneering MIT gamma-oscillation research by Li-Huei Tsai and Ed Boyden.

## Latest updates

- **2026-03** — Closed $105M Series C led by Morningside and others to advance Spectris toward the pivotal HOPE Study readout.
- **2026-03** — Presented new Spectris data on Alzheimer's biology at the AD/PD 2026 conference.
- **2025-07** — Completed enrollment of 670 participants in the HOPE pivotal study across 70 U.S. sites.
- **2026-08** — HOPE Study topline data readout expected (per company guidance).

## Links

- Website: https://cognitotx.com
- LinkedIn: http://www.linkedin.com/company/cognito-therapeutics-inc.
- Twitter/X: https://twitter.com/cognitotx
- Facebook: https://facebook.com/cognitotherapeutics/

---

Profile page: https://yespress.io/cognito-therapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-21